Compare PGEN & DEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PGEN | DEI |
|---|---|---|
| Founded | 1998 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2013 | 2006 |
| Metric | PGEN | DEI |
|---|---|---|
| Price | $3.96 | $10.24 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 8 |
| Target Price | $8.33 | ★ $12.94 |
| AVG Volume (30 Days) | ★ 5.6M | 2.0M |
| Earning Date | 05-13-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 7.49% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.09 |
| Revenue | $230,981,000.00 | ★ $1,003,982,000.00 |
| Revenue This Year | $1,115.92 | $2.29 |
| Revenue Next Year | $81.04 | $2.04 |
| P/E Ratio | ★ N/A | $112.89 |
| Revenue Growth | N/A | ★ 1.77 |
| 52 Week Low | $1.23 | $9.04 |
| 52 Week High | $5.47 | $16.94 |
| Indicator | PGEN | DEI |
|---|---|---|
| Relative Strength Index (RSI) | 50.55 | 63.31 |
| Support Level | $3.49 | $9.17 |
| Resistance Level | $4.44 | $10.59 |
| Average True Range (ATR) | 0.31 | 0.31 |
| MACD | 0.02 | 0.13 |
| Stochastic Oscillator | 57.83 | 90.44 |
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
Douglas Emmett Inc is an integrated, self-administered, and self-managed REIT. The group focuses on owning, acquiring, developing, and managing a substantial market share of office properties and multifamily communities in neighborhoods with supply constraints, high-end executive housing, and key lifestyle amenities. Its properties are located in the Beverly Hills, Brentwood, Burbank, Century City, Olympic Corridor, Santa Monica, Sherman Oaks/Encino, Warner Center/Woodland Hills and Westwood submarkets of Los Angeles County, California, and in Honolulu, Hawaii. It has two business segments: the office segment and multifamily segment, of which Office segment derives maximum revenue.